Rebastinib shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines. Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1. Molecular Formula: C30H28FN7O3 Solubility: Methanol (Slightly) Molecular Weight: 553.59 Storage and Stability: Store at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molecular Weight:
553.59
Form:
Supplied as a Off-White Solid
CAS Number:
[1020172-07-9]
* VAT and and shipping costs not included. Errors and price changes excepted
